Suggested remit: To appraise the clinical and cost effectiveness of sodium thiosulfate within its marketing authorisation for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy.
Status Proposed
Process STA 2018
ID number 1001

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
23 January 2020 - 20 February 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance